# A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes

> **NCT00001438** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (—)

## Conditions studied

- HIV Infections
- Immunologic Deficiency Syndromes
- Lymphoproliferative Disorders

## Interventions

- **DRUG:** all-trans-retinoic acid with IFN-alpha2a

## Key facts

- **NCT ID:** NCT00001438
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-06
- **Primary completion:** —
- **Final completion:** 2000-12
- **Target enrollment:** 30 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001438, "A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00001438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*